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Over 40 years of scientiﬁc evidence indicates that methyl methacrylate (MMA) causes olfactory effects in
rodents that are relevant to humans. More recent scientiﬁc studies have focused on understanding the
apparent lack of species concordance between the rodent and human studies. Toxicokinetic studies
and a physiologically based pharmacokinetic (PBPK) model describing inhalation dosimetry of MMA in
the upper respiratory tract (URT) of rats and humans point to differences in nasal morphology and
biochemistry that could explain and reconcile these differences as species-speciﬁc manifestations of a
common toxicological process. We have applied the hypothesis-based weight-of-evidence (HBWoE)
approach to evaluate the concordance of the available data and the hypothesis that the observed difference
in sensitivity between rats and humans may be the expected result of physiological and biochemical differ-
ences. Our WoE analysis indicates that when the several lines of evidence (i.e., animal, human, mode-of-
action, and toxicokinetics data) are integrated, they inform interpretation of one another and, overall, sup-
port use of the human data for derivation of an MMA occupational exposure level (OEL) of 50 ppm.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Methyl methacrylate (MMA) is a high production volume chem-
ical that has been in commerce for over 65 years and is used solely in
themanufacture of acrylic-basedhomopolymers (polymethylmeth-
acrylate) or co-polymers. These polymers are subsequently manu-r Inc.
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Open access under CC BY-NC-NDfactured into plastic articles, as well as a wide range of industrial,
professional, and consumer products. Relatively small quantities
of liquid MMA are used in some skilled-trade, medical, dental, and
hobbyist products.
MMAhasbeen studiedextensivelyover thepast 40 years. Several
comprehensive reviews have been conducted, including the
European Union’s (EU) Existing Substances Risk Assessment (CEC,
1993), the Organisation for Economic Co-operation and Develop-
ment’s Screening Information Dataset (OECD, 2003), and, more
recently, the registration of MMA under the EU’s Registration,
Evaluation, Authorisation and Restriction of Chemicals regulation
(EC, 2006). In the 1970s, considerable research was conducted on
MMA, including a range of repeat-dose studies (NTP, 1986; Chan
et al., 1988; IARC, 1994; Hazelton, 1979a, 1979b; Lomax, 1992).
These studies identiﬁeda sensitive lesion in the olfactory epithelium
of rats thatwas subsequently studied in depth. BecauseMMA is gen-
erally regarded as being of low toxicity, occupational exposure stan-
dards for acceptable vapor levels in the workplace have historically
been established with regard to worker tolerance of acute irritation
of the upper respiratory airways. More recent exposure-standards
reviews have been challenged by analyses citing the relatively large
amount of rodent inhalation, human experience, and clinical data,
and the seeming discordance between exposures causing acute
respiratory tract lesions in rats and humans. On the other hand, tox-
icokinetic studies and a physiologically based pharmacokinetic
(PBPK) model for MMA in the upper respiratory tract (URT) license.
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larynx, and trachea) of rats and humans point to species differences
in URT morphology and biochemistry that could explain these
differences. We have therefore undertaken a weight-of-evidence
(WoE) approach to evaluate the qualitative and quantitative concor-
dance of the available data, and to consider the hypothesis that the
observed differences in sensitivity between rats and humans are
explicable by differences in target-tissue dosimetry that result from
physiological and biochemical differences between these species.
Our analysis is aimed at developing a robust, science-based recom-
mendation for anoccupational standard forMMAthat reconciles the
rodent and human ﬁndings. We have intentionally not addressed
compliance and socio-economic aspects that might be considered
during the setting of a regulatory standard.
The hypothesis-based weight-of-evidence (HBWoE) approach
we employ stresses that when using effects seen in animals as evi-
dence for potential effects in humans, one is invoking the hypoth-
esized commonality of the agent’s potential actions across settings.
The animal experiments constitute evidence because they raise the
possibility that, owing to fundamental mammalian similarities in
anatomy, physiology, and biochemistry, the reactions to exposure
observed in animals would be paralleled in humans. The evidence
for qualitative hazard in humans improves to the extent that this
presumed commonality across species in the basic causative bio-
logical processes can be experimentally conﬁrmed to operate con-
sistently across settings. Conﬁdence in the characterization of
exposure-dependent toxicity is enhanced to the degree that it
can be shown to be quantitatively (not just qualitatively) consis-
tent across species and exposure regimens once one has examined
and allowed for the patterns of quantitative differences in dosime-
try. Breathing rates, airﬂows, and metabolic activity affect the rel-
ative target-tissue exposures in animals and humans for a given air
concentration inhaled. Since animal and human observations ap-
pear to show the same causal processes producing toxicity, and
allowing for known quantitative differences in these determinants
makes exposure–effect relationships consistent across species and
dosing regimens, one can base the characterization of exposure
limits on comprehensive data, rather than choosing one or another
dataset as the basis. Establishing this generality of causative pro-
cesses makes the determination more rigorous, decreases the con-
cern about which particular dataset was chosen to set a standard,
and overcomes doubt about potential uncertainties associated
with any one dataset.
We have followed this approach in the present analysis. Accord-
ingly, we proceed by stepping through the various sources of data,
asking speciﬁc questions about data quality, whether the data
should be considered dependable and consistent among available
studies, and whether the consistency of causative processes indeed
seems to hold across dosing regimens and species. We ﬁrst con-
sider MMA inhalation toxicity in the setting of acute, sub-acute,
sub-chronic, and chronic animal exposure studies. The apparent
determinants of toxicity in these settings, including the role of
the uptake and metabolism, are then reviewed with what is known
about animal-human differences in these processes. We take into
account the available data from humans and ask whether this
experience is indeed consistent with the notion of common under-
lying causes of toxicity across rodents and humans. Finally, we
consider alternatives that have been put forth for development of
recommended limits to human exposure that would be based on
the various sources of data, showing that they are consistent when
allowances for pharmacokinetics are made. In fact, considering the
obvious differences between rodent and human nasal morphology
and breathing patterns, it is not surprising that the PBPK model
predicts signiﬁcant differences between rodents and humans. Fur-
ther, extrapolation of animal-to-human effects based on the PBPK
model yields toxicity values very similar to those derived fromthe human data. We conclude that a standard based on actual
observations of workers forms the best basis. The robustness of
this standard is supported by considering how it is consistent with
a common toxicity-generating process and pattern of exposure
dependence across human and animal studies.2. Materials and methods
We conducted a literature search in PubMed, Scopus, Toxline,
and EMBASE using combinations of the following terms: methyl-
methacrylate, methyl methacrylate, animals, humans, toxicity,
toxicology pharmacokinetics, PBPK, mechanisms, mode of action,
toxicokinetics, metabolism, absorption, uptake, distribution, elim-
ination, excretion, dose, dosimetry, dose–response, models, mod-
eling, computational ﬂuid dynamics, inhalation, inhaled, nasal,
nose, respiratory, olfactory, rhinitis, vapor, vapour, air, and occu-
pational. Titles and abstracts of the search results were reviewed
to identify key studies in support of the MMA WoE analysis. We
narrowed the results to relevant publications that focus on the
following:
 inhalation exposures or respiratory tissues; studies using other
routes (e.g., intravenous, subcutaneous, dermal, or oral) were
excluded;
 endpoints of the respiratory system, nasal passages, olfactory
system, lungs, and bronchial system;
 mammalian species and humans; other species were excluded;
 MMA metabolism and mode of action; and
 MMA inhalation dosimetry and PBPK modeling.
We also reviewed the United States Environmental Protection
Agency’s (US EPA) Toxicological Proﬁle for MMA (US EPA, 1998)
and the recent MMA Health-Based Recommended Occupational
Exposure Limit document (Health Council of the Netherlands,
2011) for additional relevant documents.
We reviewed and summarized the selected studies and applied
a modiﬁed version of our HBWoE approach. This focuses predom-
inantly on overall study quality and relative consistency within
and across various lines of evidence, asking several questions that
should be considered in extrapolating results in rodents to poten-
tial human risk. The speciﬁc HBWoE evaluation approach is de-
scribed in more detail in our recent publications (Rhomberg
et al., 2010, 2011; Prueitt et al., 2011).
The results of the WoE analysis were further considered in
deriving an occupational exposure level (OEL) for MMA.3. Studies in animals
3.1. Acute studies
The acute systemic toxicity of MMA by the inhalation route is
low, as indicated by several studies conducted before the establish-
ment of OECD guidelines, reporting a lethal concentration 50 (LC50)
(4-h) of greater than approximately 6000 ppm (25 mg/L) in rats
(Tansy et al., 1980a). Systemic effects were not well documented
and, where mentioned, tended to be non-speciﬁc in nature, with
depression, ataxia, and excessive salivation being reported in mice
(Spealman et al., 1945). Local effects in the form of lesions in the
olfactory region of the nasal cavity were observed following acute
(6-h) inhalation of MMA in F344 rats at 200 ppm (948 mg/m3)
(Jones, 2002). Comparable lesions were also observed in the main
olfactory region (turbinates) of the nasal cavity, as well as the or-
gan of Rodolfo Masera (a small island of olfactory epithelium, sur-
rounded by respiratory epithelium, lying near the ventral base of
the nasal septum at the entrance to the nasopharynx of some
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of MMA in Wistar rats at 400 ppm (3792 mg/m3) (Robinson et al.,
2003). Studies are summarized in Table 3.1.3.2. Sub-acute and sub-chronic studies
In sub-acute inhalation studies of MMA in rats and mice (sum-
marized in Table 3.2), systemic toxicity was limited to reduced
body weight at 1000 ppm in mice and at P2000 ppm in rats
(NTP, 1986). In sub-chronic inhalation studies of MMA (summa-
rized in Table 3.2), systemic toxic effects were seen in F344 rats
at P1000 ppm (Battelle, 1980). These effects included degenera-
tive and necrotic lesions in the liver, kidney, and brain, and
atrophic changes in spleen and bone marrow. Although compara-
ble effects were reported in sub-chronic inhalation studies in
B6C3F1 mice at P500 ppm, these effects were not conﬁrmed in a
chronic study, in which no increases in lesions were observed up
to 1000 ppm (NTP, 1986). There appears to be no consistent sys-
temic target organ of note.
In a 28-day time-course and recovery study, olfactory damage
was observed in F344 rats exposed (whole-body) for 6 h/day to 0,
110, or 400 ppm MMA (99.9%) (equivalent to 0, 0.017 and
1.68 mg/L, respectively) for 1, 2, 5, 10, or 28 consecutive days (Hext
et al., 2001). A matching group of 5 animals was allowed to recover
for 4, 13, 24, or 36 weeks before sacriﬁce. Moderate olfactory dam-
age was observed at 400 ppm, with only very slight damage at
110 ppm after 6 h of exposure, with no increase in severity of ef-
fects over the 28 days of treatment. Recovery (epithelial regenera-
tion) was seen in the 110 ppm exposed animals by day 5 of
exposure and was complete by day 28. Recovery was also observed
as early as day 2 of exposure in the 400 ppm group, although this
was incomplete, with subsequent development of extensive respi-
ratory metaplasia and adhesions between the septum and turbi-
nate in 3 out of 5 animals.
In another study (Aydin et al., 2002), local effects in the nasal
cavity and the bronchus were observed in adult female Wistar rats
following whole-body exposure to 1000 ppm MMA (99.9%) for 6 h/
day, 5 days/week for 4 weeks. Effects compared to controls were
more marked in animals that received MMA vapor under poor ven-
tilation conditions and higher levels of MMA than in those exposed
under normal ventilation conditions.
Local effects were also observed in the nasal cavities of F344
rats and B6C3F1 mice in 14-week, inhalation dose-sighting studies
with MMA (Battelle, 1980; NTP, 1986). Groups of 10 male and 10
female rats and mice were exposed to 0, 500, 1000, 2000, 3000,
or 5000 ppm (equivalent to 0, 2.1, 4.2, 8.3, 12.5, and 20.8 mg/L,
respectively) MMA. Inﬂammation in the nasal cavity with corre-
sponding necrosis and loss of olfactory epithelium was observed
in both rats and mice at 2000 ppm (equivalent to 8.3 mg/L). Olfac-
tory damage at lower concentrations was not reported. Acute lar-
yngitis, tracheitis, and congestion and hemorrhage of the lung
were also observed with increasing frequency above 2000 ppm.Table 3.1
MMA acute inhalation studies in rats.
Reference Rat strain Study design MMA exposure
levels (ppm)
NO
(pp
Tansy et al.
(1980a)
Sprague–
Dawley
4-h, whole-body exposure;
group size = 10 animals
4750; 6146; 8044;
10,208; 13,479
–
Jones
(2002)
Fischer 344
(225–250 g)
6-h, whole-body exposure;
5 M per dose group
0, 200 (193–194
mean measured)
–
Robinson
et al.
(2003)
Wistar (6–
8 weeks old)
4-h, nose-only exposure;
5 M per dose group
400 –
Note: NOAEL, no observed adverse effect level; LOAEL, lowest observed adverse effect leTansy et al. (1980b) exposed one group of rats to 116 ppm
(equivalent to 500 mg/m3) MMA for 3 and 6 months, and exposed
another group of 10 rats to 1000 ppm (4100 mg/m3) for 56 h over a
7-day period. Frank lung damage characterized by adherence of the
visceral pleura to the parietal pleura, as well as ﬁbrosis, lung ede-
ma, and parenchymal changes suggestive of emphysema, were ob-
served in some treated animals exposed to 1000 ppm MMA and, to
a lesser degree, in some sham-exposed controls. Occasional similar
lung damage was observed to a lesser degree in animals exposed to
116 ppm for 3 or 6 months, but similar effects were also observed
in sham-exposed controls. Histological examination of the URT of
the animals exposed to 116 ppm for 6 months showed damage to
the tracheal mucosa in all 6 treated animals but not in sham-ex-
posed controls. These small areas of focal hemorrhage were exam-
ined by scanning electron microscopy, revealing reduced microvilli
and denuded cilia. No such effects were evident in the 3-month
exposure group or sham-control animals. In the same study, mice
were also exposed to up to 400 ppm MMA continuously for 160 h.
No effects were observed other than a slight alteration of sodium
phenobarbital detoxiﬁcation in the liver with no dose–response
(Tansy et al., 1980b).
No exposure-related microscopic changes were observed in the
nasal cavities, including the olfactory epithelium, or other organs
(>35 tissues examined) among golden hamsters exposed to 0, 25,
100, or 400 ppm (0, 102.5, 410, or 1640 mg/m3, respectively)
MMA for 6 h/day, 5 days/week for 78 weeks (Hazelton, 1979a; Lo-
max et al., 1997) (Tables 3.2 and 3.4).
No exposure-related microscopic changes were observed in the
nasal turbinatesof beagledogsexposed to0, 100, or 400 ppm(equiv-
alent to 0, 410 or 1640 mg/m3, respectively) MMA for 6 h/day,
5 days/week for 3 months (Hazelton, 1979b).3.3. Chronic studies
Local effects were observed in a 2-year combined inhalation
chronic-toxicity/carcinogenicity study with MMA in F344 rats
(Hazelton, 1979b). Groups of 70 male and 70 female rats were ex-
posed to vapor concentrations of 0, 25, 100, or 400 ppm (0, 102.5,
410, or 1640 mg/m3, respectively) MMA for 6 h/day, 5 days/week
for 2 years. Interim sacriﬁces of 10 male and 10 female rats from
each group occurred at 13 and 52 weeks of exposure; all surviving
rats were killed during weeks 104–106. Histological examination
was conducted on more than 35 tissues, including the lungs and
3–4 cross-sections of the nasal cavity. Tissues from the trachea
and the pharynx/larynx were not preserved for histopathologic
examination. A very slight increase in lesions of mild rhinitis was
observed in the nasal mucosa lining the turbinates, and areas of
squamous metaplasia were observed in seven of the 400 ppm ex-
posed rats and in two controls. There were no effects observed in
the lungs or for any other parameter examined. The nasal tissue
blocks were subsequently recut and re-evaluated according to cur-
rent approaches (Lomax, 1992; Lomax et al., 1997). Nasal lesionsAEL
m)
LOAEL
(ppm)
Effects
– LC50 7093 ppm
200 Degeneration in olfactory epithelium lining, central septum,
and ethmoturbinates 4 & 5 in level 4
400 Nasal epithelium lesions (medial posterior cavity, localized to
the septum and tips of the 3rd–5th ethmoturbinates)
vel; M, males.
Table 3.2
MMA Sub-acute and Sub-chronic Inhalation Studies in Animals.
Reference Species Study design MMA exposure
levels (ppm)
[purity]
NOAEL
(ppm)
LOAEL
(ppm)
Effects
Rats
Battelle (1980) Fischer 344 (120–165 g) 6 h/day, 5 days/week for
13 weeks; 10 M/10 F per dose
group
0; 500; 1000;
2000; 3000;
5000 [99.68–
99.91%]
500 1000 Degenerative lesions in nasal
turbinates
Tansy et al. (1980b) Sprague–Dawley (90–100 g) 56-h exposure over 7 days; 10 M
interrupted, 9 M sham-exposed
0; 1000 – 1000 Altered blood chemistry, lung
damage (ﬁbrosis, edema,
emphysema)
Sprague–Dawley (174–216 g) 7 h/day, 5 days/week for 542 h;
23 M per dose group, sham-
exposed
0; 116 (mean
measured
concentration)
– 116 Higher average fecal excretion in
exposed animals
Sprague–Dawley (90–100 g) 8 h/day, 5 days/week for 3 or
6 months
0; 116; 400
(mean
measured
concentration)
– 116 Damage to tracheal epithelium
NTP (1986) Fischer 344 (6 weeks old) 6 h/day for 10 exposures; 5 M/5 F
per dose group
0; 500; 1000;
2000; 3000;
5000 [>99%]
1000 2000 Body weight change (10–19%
lower than controls)
Fischer 344 (8 weeks old) 6 h/day for 9 exposures; 5 M/5 F
per dose group
0; 75; 125; 250;
500; 1000
[>99%]
1000 – No compound-related clinical
signs or gross pathological effects
observed
Fischer 344 (8 weeks old) 6 h/day, 5 days/week for 64
exposure days; 10 M/10 F per dose
group
0; 63; 125; 250;
500; 1000
[>99%]
1000 – No compound-related clinical
signs or gross pathological effects
observed
Hext et al. (2001) Fischer 344 (5–6 weeks old) 6 h/day whole-body exposure for
1, 2, 5, 10, or 28 days; 5 F per dose
group
0; 110; 400 (0;
115; 390 mean
measured)
[99.9%]
– 110 Slight degeneration/necrosis of
olfactory epithelium (lesions
repaired during exposure period)
Aydin et al., 2002 Wistar (250–300 g) 6 h/day, 5 days/week for 4 weeks;
11–12 F per dose group, 2 groups;
A: poor ventilation (sealed 0.9 L
glass chambers without
ventilation pores) and B: normal
ventilation (sealed 0.9 L glass
chambers with ventilation pores)
0; 1000 [>99%] – 1000 Degeneration of olfactory
epithelium, bronchopneumonia,
interstitial pneumonia,
hemorrhage, atelectasis, edema,
emphysema, and bronchial
epithelial hyperplasia
Mice
Tansy et al. (1980b) Swiss-Webster (20–25 g) Daily exposure for 160 h for
6.6 days (sham or interrupted
exposures)
0; 100; 400 – 100 Slight alteration of sodium
phenobarbital detoxiﬁcation in
the liver but no dose–response
Battelle (1980) B6C3F1 (26–29 g) 6 h/day, 5 days/week for
13 weeks; 10 M/10 F per dose
group
0; 500; 1000;
2000; 3000;
5000 [99.68–
99.91%]
1000 2000 Mortality; lesions in nasal
turbinates and lungs; congestion
in lungs and brain
NTP (1986) B6C3F1 (8 weeks old) 6 h/day for 9 exposures; 5 M/5 F
per dose group
0; 75; 125; 250;
500; 1000
[>99%]
1000 – No compound-related clinical
signs or gross pathological effects
observed
B6C3F1 (8 weeks old) 6 h/day, 5 days/week for 64
exposure days; 10 M/10 F per dose
group
0; 63; 125; 250;
500; 1000
[>99%]
500 1000 Body weight (7% lower than
controls); no other effects
observed
B6C3F1 (6 weeks old) 6 h/day for 10 exposures; 5 M/5 F
per dose group
0; 500; 1000;
2000; 3000;
5000 [>99%]
– 500 Mortality, dyspnea, redness and
swelling of nasal region
Hamsters
Hazelton (1979a),
Lomax et al., 1997
Golden (juvenile) 6 h/day, 5 days/week for
78 weeks; 56 M/56 F per dose
group
0; 25; 100; 400
[99.64%]
100 400 Mortality through 32 weeks; no
other changes noted
Beagle dogs
Hazelton (1979b) 25–29 weeks old 6 h/day, 5 days/week for
3 months; 2 M per dose group
0; 100; 400
(average
measured
concentrations:
116 and 440)
400 – No effects in nasal turbinates
Note: NOAEL, no observed adverse effect level; LOAEL, lowest observed adverse effect level; M, males; F, females.
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sure groups and were characterized by inﬂammatory degeneration
of nasal epithelium. The primary target tissue was the olfactory
epithelium, with degeneration and/or atrophy of neurogenic epi-
thelium and submucosal (Bowman’s) glands lining the dorsal mea-
tus, hyperplasia of basal cells, replacement of olfactory epitheliumwith ciliate (respiratory-like) epithelium (metaplasia), and inﬂam-
mation of the mucosa and/or submucosa. The severity of the le-
sions was reported to vary from minimal to slight at 100 ppm
(416 mg/m3) and minimal to moderate at 400 ppm (1664 mg/m3)
(see Table 3.3). The no observed adverse effect level (NOAEL) for lo-
cal effect was 25 ppm (104 mg/m3).
Table 3.3
Frequency of nasal lesions in F344 rats exposed to MMA vapor for two years (Lomax, 1992).
Males Females
MMA concentration (ppm) 0 25 100 400 0 25 100 400
Olfactory epithelium
No. of animals examined 39 47 48 38 44 45 41 41
Degeneration/atrophy 0 0 86% 100% 0 0 59% 95%
Basal cell hyperplasia 13% 6% 69% 87% 0% 2% 44% 76%
Inﬂammation (chronic, mucosal, & submucosal) 0% 0% 35% 76% 0% 0% 12% 61%
Olfactory replaced by ciliate epithelium (metaplasia) 0% 0% 2% 39% 0% 0% 17% 51%
Respiratory epithelium
No. of animals examined 44 47 48 42 45 45 41 42
Hyperplasia, submucosal gland, & goblet cell 2% 0% 2% 60% 0% 0% 2% 21%
Inﬂammation (chronic, mucosal, & submucosal) 9% 0% 4% 60% 4% 0% 0% 21%
Table 3.4
MMA chronic inhalation studies in animals.
Reference Species Study design MMA exposure levels
(ppm) [purity]
NOAEL
(ppm)
LOAEL
(ppm)
Effects
Rats
NTP (1986), Chan
et al. (1988)
Fischer
344 (7–
8 weeks
old)
6 h/day, 5 days/week for
102 weeks; 50 M/50 F
per dose group
0; 250; 500; 1000
(249, 499, 984 mean
measured) [>99%]
– 250
(M)
500 (F)
Inﬂammation of nasal cavity and degeneration of olfactory
epithelium
Lomax (1992),
Lomax et al.
(1997),
Hazelton
(1979b)
Fischer
344
(juvenile)
6 h/day, 5 days/week for
24 months; 70 M/70 F
per dose group
0; 25; 100; 400 (0, 25,
99.8, 396.1 mean
measured) [99.64%]
25 100 Degeneration of olfactory neuroepithelium in the nasal
cavity
Mice
NTP (1986), Chan
et al. (1988)
B6C3F1
(8–
9 weeks
old)
6 h/day, 5 days/week for
102 weeks; 50 M/50 F
per dose group
0; 500; 1000 (499, 984
mean measured)
[>99%]
– 500 Olfactory epithelium degeneration, inﬂammation and
epithelial hyperplasia of nasal cavity, cytoplasmic
inclusion of nasal mucosa, lung inﬂammation at
1000 ppma
Hamsters
Lomax et al. (1997) Golden
(juvenile)
6 h/day, 5 days/week for
18 months; 53–56 M/
56–59 F per dose group
0; 25; 100; 400 (0,
24.8, 100.1, 398.7
mean measured)
[99.64%]
400 – No demonstrable nasal cavity changes
Note: NOAEL, no observed adverse effect level; LOAEL, lowest observed adverse effect level; M, males; F, females.
a Effects in the lung are observed at concentrations higher than the LOAEL for nasal and olfactory epithelial effects.
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MMA in 2-year inhalation cancer bioassay studies in F344 rats
and B6C3F1 mice (NTP, 1986; Chan et al., 1988) (Table 3.4). Groups
of 50 male rats and 50 male and female mice were exposed for 6 h/
day, 5 days/week to MMA at target concentrations of 0, 2.1, or
4.2 mg/L (0, 500, or 1000 ppm, respectively) for 102 weeks. Groups
of 50 female rats were exposed at concentrations of 0, 1.0, or
2.1 mg/L (0, 250, or 500 ppm, respectively) on the same schedule.
Increased incidences of serous and suppurative inﬂammation of
the nasal cavity and degeneration of the olfactory sensory epithe-
lium (characterized by loss of neuroepithelial cells) were observed
in male rats at 500 or 1000 ppm and in female rats at 250 or
500 ppm. In exposed male and female mice, inﬂammation of the
nasal cavity, epithelial hyperplasia in the nasal mucosa, and degen-
erative changes of the olfactory sensory epithelium were reported
at P500 ppm. No compound-related effects were reported for the
trachea and larynx in rats or in mice up to 1000 ppm, although
interstitial inﬂammation of the lung was observed in male mice
at 1000 ppm. No NOAEL for local effects was established in rats
and mice in the National Toxicology Program (NTP, 1986) study.
3.4. Conclusion
Overall, degenerative lesions of the main olfactory epithelium
in the posterior nasal cavity (turbinates) appear to be the mostsensitive adverse effect in animals following inhalation of MMA va-
pors, with evidence of a concentration threshold for this effect and
no indication of an increased sensitivity with duration of exposure.
From the available data in rats, the lowest observed adverse effect
level (LOAEL) for this effect is 100 ppm, and the NOAEL is 25 ppm
whether exposure is acute (6 h) or chronic (up to 2 years’ duration)
(Lomax, 1992). Local effects in the nasal respiratory epithelium
(inﬂammation and hyperplasia) were also observed in the 2-year
inhalation cancer bioassay studies in rats and mice at exposure
concentrations higher than those fromwhich olfactory effects were
observed. The Lomax (1992) study suggests a NOAEL of 100 ppm
for respiratory epithelial effects.4. Mode of action in animals
In acute- and repeated-exposure inhalation studies in vivo (pre-
dominantly in rats), MMA causes dose-related lesions in the nasal
epithelia of the URT that are mainly conﬁned to the olfactory re-
gion. The localization of this lesion contrasts with what is typically
observed with highly reactive, water-soluble toxicants like sulphu-
ric acid, hydroﬂuoric acid, acrylic acid (AA) (ECJRC, 2002a), and
methacrylic acid (MAA) (ECJRC, 2002b), as these chemicals tend
to cause concentration-dependent toxicity, predominantly in the
anterior region of the nose where the concentration is highest.
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observed following exposure to a relatively large number of organ-
ic compounds, including hydrocarbons, chlorocarbons, mono- and
dibasic-esters, and acetates, all of which require localized metabo-
lism at speciﬁc sites within the nasal epithelium before exerting
their toxicity (Miller et al., 1984; Stott and McKenna, 1985; Keenan
et al., 1990; Hardisty et al., 1999). This is because some enzyme
activities, including esterases and cytochrome P450 oxidases, are
present in sites within the nose at concentrations nearing or even
higher than their concentrations in other tissues (Dahl et al., 1982,
1987; Simon et al. 1985; Bogdanffy, 1990; Dahl and Hadley, 1991).
It is generally recognized that carboxylesterases are a group of
non-speciﬁc enzymes that are widely distributed throughout the
body and are known to show high activity within many tissues
and organs, including the liver, blood, gastrointestinal tract, nasal
epithelium, and skin. Their physiological function is to mediate
the hydrolysis of both exogenous and endogenous compounds
with an ester, amide, or thioester bond (Satoh and Hosokawa,
1998; Junge et al., 1975). Carboxylesterases have been shown to
mediate the hydrolysis of MMA to MAA and methanol in several
tissues in vitro (Corkill et al., 1976; McCarthy and Witz, 1991,
1997). Hydrolysis of MMA has also been shown to be rapid (Jones,
2002), and therefore, an early, if not initial, step in its metabolism
in rats (Bratt and Hathway, 1977). The same conclusion was drawn
after it was discovered that the proﬁle of plasma levels of MMA
leaching from hip replacement cements in patients was closely fol-
lowed by the plasma level proﬁle of MAA (Crout et al., 1979).
It has been hypothesized that with high concentrations of carb-
oxylesterases present in the nasal epithelial tissue (Bogdanffy
et al., 1987; Frederick et al., 1994; Lewis et al., 1994), MMA is
metabolized to MAA, which, as an organic acid, has tissue irritant
and corrosive properties. This localized metabolism leads to MAA
accumulation in the tissue, which could induce tissue degeneration
if it reaches a sufﬁciently high concentration.
Evidence supporting this hypothesized mode of action comes
from studies with the carboxylesterase inhibitor Bis-(p-nitro-
phenyl) phosphate (BNPP). F344 rats pre-treated with BNPP
(100 mg/kg, intraperitoneally, Büch et al., 1969) prior to whole-
body exposure to 200 ppmMMA vapor for 6 h showed signiﬁcantly
reduced carboxylesterase activity in the nasal epithelium in vivo
and concomitantly decreased severity of nasal lesions when com-
pared to MMA-exposed controls (Mainwaring et al., 2001).
Further evidence comes in the form of studies on the effect of
BNPP on MMA extraction by the URT of rodents. It has been ob-
served that when the level of metabolism is sufﬁciently high, it
can become rate-limiting on MMA extraction in the URT (Morris,
1990, 1992; Morris and Frederick, 1995; Büch et al., 1969). Depo-
sition of MMA vapor in the surgically isolated URT (all sections
anterior to and including the larynx) of urethane-anaesthetized
F344 rats was studied after constant-velocity, unidirectional ﬂow
(200 L/min) or cyclic ﬂow (207 mL/min mean respiratory ﬂow rate)
inhalation of 90, 437, and 2262 mg/m3 MMA (Morris, 1992). Pre-
treatment in vivo (100 mg/kg, intraperitoneally) with BNPP (Büch
et al., 1969) had previously been shown to produce approximately
60% inhibition of nasal carboxylesterase activity without altering
uptake of non-metabolized vapors. Deposition efﬁciencies in rats
without BNPP pre-treatment averaged 10–20% under both ﬂow
conditions, with lower efﬁciency at the higher exposure concentra-
tions. BNPP pre-treatment signiﬁcantly reduced deposition by 2–
8% under both ﬂow regimens, showing some dependency of URT
uptake on tissue carboxylesterase activity (Morris, 1990). Morris
and Frederick later reported conﬁrmatory studies with MMA in
F344 rats, with and without BNPP pre-treatment. Without BNPP
pre-treatment, URT deposition efﬁciencies averaged 16–20% under
cyclic ﬂow conditions, with 3% less under unidirectional ﬂow.
BNPP pre-treatment reduced deposition by one-third. MMAexposure at 566 ppm and absolute deposition rates of 35–42 lg/
min under unidirectional ﬂow also resulted in a 20% lowering of
nasal non-protein sulfhydryl (NPSH) content indicative of direct
protein reactivity, whereas MAA exposures had no effect, even at
higher delivered dose rates (Morris and Frederick, 1995).
The mode of action involving metabolism of the parent chemi-
cal by carboxylesterases present in the olfactory epithelium lead-
ing to localized concentration of a toxic metabolite has been
demonstrated for other volatile chemicals, including vinyl acetate
(VA) (Plowchalk et al., 1997; Bogdanffy and Taylor, 1993) and ethyl
acrylate (EA) (Frederick et al., 1994; Morris and Frederick, 1995).
Hence, while MMA depletion of NPSH or covalent binding to mac-
romolecules may play some role in initiating olfactory toxicity
(Frederick et al., 1994), it would appear that the reported metabo-
lism of MMA to MAA in the nose, and evidence for similar olfactory
damage caused by the acid versus the ester (Miller et al., 1981,
1985) strongly suggest an acid metabolite-dependent mechanism
for olfactory toxicity.
4.1. Conclusion
The animal mode-of-action data suggest that inhaled MMA is
metabolized to MAA in the nasal epithelial tissue due to the pres-
ence of high concentrations of carboxylesterases. Thus, localization
and metabolism of MMA in nasal tissue leads to MAA accumula-
tion and tissue degeneration.
It is generally recognized that carboxylesterases are a group of
non-speciﬁc enzymes that are widely distributed throughout the
animal and human body. Given that esterase activity occurs in hu-
man nasal epithelium, and because the types of nasal epithelial
cells found in rats are similar to those of other mammalian species,
it is likely that the mode of action for MMA toxicity in the nose of
rodents is relevant to humans, as discussed in the later sections.5. Human studies
5.1. Respiratory sensitization
The published database on adverse health effects in humans fol-
lowing exposure to MMA, despite being relatively large, is focused
mainly on the potential for MMA to cause contact (skin) or respira-
tory (asthma) allergies. Since there are no validated animal models
for the identiﬁcation of lowmolecular weight respiratory allergens,
and the threshold to elicitation of asthmatic responses in individ-
uals who are respiratory-sensitized is reported to be typically at
least an order of magnitude below the NOAEL for olfactory effects
observed in rodents (25 ppm), it is important to be able to establish
whether these reported responses are indicative of a health effect
that is potentially more sensitive than either nasal irritation or
olfactory degeneration. The EU Risk Assessment Report (European
Union, 2002) and the extensive recent review by Borak et al. (2011)
concluded that there is no convincing evidence that MMA is a
respiratory sensitizer in humans and that the effects reported are
likely due to local, primary irritation.
5.2. Respiratory irritation
There are several studies that report symptoms indicative of
respiratory irritation in workers occupationally exposed to MMA
vapor. Although these studies do include relatively comprehensive
exposure data that point to the threshold for this effect in humans
being P100 ppm, the wide range in exposure levels prevents it
from being determined with any degree of precision.
Non-speciﬁc irritation of the respiratory tract, along with weak-
ness, fever, dizziness, nausea, headache, and sleepiness, was
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90 min of inhalation of MMA vapor at average concentrations be-
tween 48 and 480 ppm (0.197–1.968 mg/L) (Karpov, 1954, 1955).
A letter by Coleman (1963) to the American Conference of Indus-
trial Hygienists (ACGIH) Threshold Limit Values (TLV) committee
suggests that the threshold for irritation (not speciﬁed) in workers
in the same industry in the US is around 175 ppm.
Irritation of the nose (runny nose) or throat (phlegm or sensi-
tive throat), without changes in lung function, was observed in 3
out of 10 ﬂoor-layers regularly exposed to MMA concentrations be-
tween 62 and 601 ppm for intervals of approximately 20 min fol-
lowed by a period of no exposure of between 30 and 60 min
(Lindberg et al., 1991).
In a study examining workers involved in the manufacture of
poly-MMA acrylic sheet and liquid MMA-based composites (Pick-
ering et al., 1993), non-speciﬁc nasal irritation was reported in
18 out of 259 (6.9%) of those with moderate to high exposures to
MMA and in 98 out of 268 (36.6%) workers exposed to cell bursts
or other transient high exposures of MMA. Pickering et al. (1993)
also found a low prevalence of work-related respiratory symptoms,
including persistent cough (2.3%), chronic cough (1%), chest tight-
ness (3.4%), wheeze (2.3%), and breathlessness (1.8%), with a higher
tendency towards the moderate- to high-exposure category; how-
ever, smoking was a likely confounding factor. Exposure data pro-
vided by the company to the EU, under the Existing Substances
Risk Assessment Regulation, reported median exposures to
approximately 11 ppm with a 95th percentile of 59 ppm [8-h shift
time-weighted average (TWA)] for all workers and all tasks (low-
to high-exposure) in the preceding years up to the study, as well
as occasional peak exposures into the several hundred ppm
(200–500) range for certain tasks, including cell breaks (European
Union, 2002).
Throat irritation was reported in 4 out of 32 male workers in a
poly-MMA cast sheet plant exposed to 0.4–112 ppm MMA (8-h
TWA), and frequent cough and sputa was reported in 6 out of 32
(Mizunuma et al., 1993). All cases were related to the high-expo-
sure group, with exposures between 5 and 112 ppm TWA; there
was no mention of short-term high-exposure levels beyond
100 ppm. Acute reversible respiratory irritation (rhinitis, impaired
nose breathing, dry nose, and bleeding of the nose), was also re-
ported in workers involved in the manufacture of poly-MMA acrylic
sheet and liquid MMA composites after exposure to short-peak
exposures in excess of 100 ppm MMA, although no data were
reported to support this correlation (Pausch et al., 1994).
The prevalence of URT effects was investigated in a cross-sec-
tional study of 211 male MMA-exposed workers at the cast acrylic
sheet facility in Germany. The study involved a medical survey
consisting of a self-questionnaire about lifestyle, occupation, and
medical history, with emphasis on complaints of nose, throat,
and respiratory system failures, and allergic reactions, including
skin irritation and asthmatic symptoms (Pausch et al., 1994). The
questionnaire was supplemented by a detailed anamnesis and
anterior rhinoscopy using a speculum. The workers (mean age
37 years) spent an average of 8.8 years (from <1 to >20 years of
employment) in acrylic sheet production. Fifty-ﬁve new workers
without any prior exposure to MMA were examined in the same
manner. Exposures (from personal air monitors) to MMA varied
between <3 and 40 ppm (<12 and 160 mg/m3), 8-h TWA. Past
exposures were between 10 and 70 ppm (41 and 290 mg/m3), 8-
h TWA. Occasional short-term peak concentrations of 100–
680 ppm (410–2800 mg/m3) had also been recorded. No case of
MMA exposure-related respiratory (asthma) or skin sensitization
was observed in the exposed groups. Observation of irritation in
the eyes and the URT was reported to be limited to acute and
reversible reactions after short-term peak exposures at concentra-
tion levels exceeding 100 ppm (410 mg/m3) (without any proof forthe correlation). There were no indications for clinical symptoms of
a work-related rhinopathy or any substance-related abnormalities
in the nasal cavity in the exposed group.
5.3. Olfactory effects
Several studies have speciﬁcally investigated the effect of occu-
pational or clinical exposure to MMA on olfactory function. These
studies are summarized in Table 5.1.
At a plant manufacturing acrylates and methacrylates, olfactory
function was studied in 731 workers (83% of available and 78% of
total employees), consisting of 618 males and 113 females with
an age range 17–69 years (mean 42.9, standard deviation of
11.3 years) and broad ethnic origins (596 Caucasian, 98 African
American, 37 Asian or Hispanic) (Schwartz et al., 1989). Exposure
was categorized by current job only and described as being to mul-
tiple chemicals (EA and AA) from 0.01 to 56 ppm, with most areas
having 8-h TWA exposures below the TLV recommended by ACGIH
for AA (10 ppm) and EA (5 ppm). Testing involved the administra-
tion of the University of Pennsylvania’s ‘‘scratch and sniff’’ smell
identiﬁcation test (UPSIT) and a questionnaire concerning shift
and job proﬁle. In the original cross-sectional (prevalence) study,
no association was found between chemical exposure and olfac-
tory test scores (p = 0.09). A nested case-control study was then
performed on 77 workers who scored 610th percentile (for their
age) on the UPSIT, compared with 77 control workers (matched
for age, sex, and ethnic group), to assess the cumulative effect of
exposure. An apparent dose-related association was found be-
tween cumulative exposure to acrylates and methacrylates and
olfactory dysfunction. Exposure odds ratios of 2.8 (1.1–7.0) and
13.5 (2.1–87.6) were calculated by logistic regression analysis for
all workers and for those who had never smoked, respectively. A
decreasing odds ratio was observed between olfactory dysfunction
and time since last exposure, indicating reversibility of the effect.
Given the mixed exposures in this study, the causative agent for
the observed olfactory effects and associated exposure levels is
uncertain.
The prevalence of smell disorders was investigated by Muttray
et al. (1997) using the Rhino-Test

(Vostra, Aachen, Germany) in a
cross-sectional study involving 175 MMA-exposed workers (smok-
ers: 58.3%; non-smokers: 32.6%; and former smokers: 9.1%) and a
comparable group of 88 non-MMA-exposed controls (smokers:
34.1%; non-smokers: 42%; and former smokers: 23.9%) at the same
cast acrylic sheet facility (Pausch et al., 1994). The Rhino-Test is
similar in design to the UPSIT (Doty et al., 1985) and involves sub-
jects being asked to identify 6 aromas delivered from spray bottles
(rather than scratch and sniff strips used in the UPSIT). Peppermint
(menthol) acts as a mixed stimulus, stimulating both the olfactory
nerve and the trigeminal nerve. The remaining 5 aromas act as a
pure stimulus on the olfactory nerve alone. All individuals, includ-
ing anosmics (individuals with the inability to smell particular
odors) are expected to detect the peppermint aroma because of
its sensory irritant properties (trigeminal nerve stimulation). The
remaining aromas provide insight into functional capacity of the
olfactory epithelium. This experimental design has proven to be
a highly reliable and internally consistent test of the sense of smell
(Doty et al., 1985; Frank et al., 2006) and has been used as a means
for clinical diagnosis of olfactory deﬁcits (Bylsma et al., 1997; Sobel
et al., 2001). The smell test was performed before, during, or just
after the shift (not speciﬁed). In the group of exposed workers, only
one case (0.6%) of hyposmia (reduced ability to smell) was ob-
served. The mean duration of exposure was 9.6 ± 7.1 years (mini-
mum 1 year, maximum 33 years). Personal air monitoring was
conducted from 1987 to 1994, which included repeated short-term
(<1 h) and long-term (>1 h) average concentrations of MMA during
the work shift from different work areas, according to the German
Table 5.1
Human olfactory effects.
Reference Location Study type Exposed
population (n)
Non-
exposed
population
(n)
Mean
exposure
duration
Inhalation tests
employed
Endpoint
examined
NOAEL LOAEL
Schwartz
et al.
(1989)
Chemical
manufacturing
facility
Cross-sectional
(prevalence)
study
193 (exposure to
other chemicals)
164 (low
acrylate/MMA
exposure) 55
(high acrylate/
MMA exposure)
319 (no
signiﬁcant
exposure)
Not assessed UPSIT Olfactory
dysfunction
0.01–56 ppm
(EA/AA/MMA)
–
Nested case-
control study
77 77 15.5 years of
employment
UPSIT Olfactory
dysfunction
– –
Pausch
et al.
(1994)
Acrylic sheet
production
facility
(Darmstadt,
Germany)
Cross-sectional
(prevalence)
study
211 males None
reported
8.8 years Questionnaire,
anamnesis, and
rhinoscopy
Eye irritation
and
lacrimation,
pharyngitis,
bronchitis,
headaches,
respiratory, or
skin
sensitization
– >100 ppm
Muttray
et al.,
1997
Acrylic sheet
production
facility
Cross-sectional
(prevalence)
study
175 MMA-
exposed male
workers
88 9.6 years Rhino-Test Olfactory
dysfunction
50 ppm –
Braun
et al.
(2002)
Orthodontic
dental
technician
Case report 45-year-old
female
0 4.75 years Ear/nose/throat
examination
Rhinitis,
inﬂammation of
the inferior
turbinates, and
olfactory
disturbance
Not measured Not
measured
Gosepath
et al.
(2007)
Mainz,
Germany
In vitro cell
culture
22 cell cultures Controls
exposed to
synthetic
air
4 or 24 h In vitro nasal cell
culture
Cytokine
release and
mRNA
induction
<50 ppm 50 ppm
Muttray
et al.
(2007)
Mainz,
Germany
Human
exposure study
(crossover
design)
20 male non-
smokers
None
reported
4 h Nasal mucus
samples and
questionnaire
Cytokine
release and
mRNA
induction,
headache, smell
50 ppm –
van Thriel
et al.
(2012)
Germany Human
exposure study
(randomized
crossover
design, 2
control and 2
environmental
exposures)
32 32 4 h Rhinomanometry Nasal airway
resistance,
nasal mucus
biochemistry
Variable
concentration
gradient
(50 ppm
average, with
4 peaks at
100 ppm)
–
Note: UPSIT, University of Pennsylvania Smell Identiﬁcation Test; NOAEL, no observed adverse effect level; LOAEL, lowest observed adverse effect level; EA, ethyl acrylate;
AA, acrylic acid.
224 M. Pemberton et al. / Regulatory Toxicology and Pharmacology 66 (2013) 217–233Technische Regel für Gefahrstoffe 402. TWA concentrations of
MMA were reported to be up to 50 ppm from 1988 to 1994 and
up to 100 ppm prior to that time. With few exceptions, workers
were reported to be exclusively exposed to MMA. The authors con-
cluded that because the number of workers who had left MMA-ex-
posed jobs was low, it was extremely unlikely that the study was
inﬂuenced by the ‘‘healthy worker’’ effect (Muttray et al., 1997).
Braun et al. (2002) reported a case of a 45-year-old female
orthodontic dental technician with clinically diagnosed rhinitis,
inﬂammation of the inferior turbinates, and disturbance of olfac-
tion (dysosmia). In the absence of any other plausible explanation
(e.g., smoking, surgery), her prior history (4.75 years) of ‘‘extensive
and sustained’’ but undocumented occupational exposure to an ac-
rylic resin containing MMA was thought to be the likely cause of
the dysfunction.
In a crossover design clinical study by Muttray et al. (2007), 20
healthy male non-smokers (median age: 25 years; range: 20–
62 years), without prior history of exposure to MMA, were exposed
in an chamber to 50 ppm MMA vapor or room air for 4 h. Thecrossover study design involved volunteers being randomly allo-
cated to treatment (MMA-exposed) or control (air-exposed) groups
during the ﬁrst week and receiving the alternative exposure regi-
men after a 1-week interval. Before and after the exposure, mucoc-
iliar transport time and the odor threshold of n-butanol were
determined with Snifﬁn’Sticks. After exposure, a sample of nasal
mucous was taken for measurement of IL-1b and IL-8, and a tissue
sample was removed from the epithelium at the base of the nose
for analysis for mRNA of different cytokines by polymerase chain
reaction (PCR). A questionnaire (ordinal scale from 0 to 5) from
the Swedish Performance Evaluation System (Iregren et al., 1996)
was administered before, during, and after the exposure. After sta-
tistical distribution analyses, parametric and non-parametric
crossover analyses were performed. Exposure to 50 ppm MMA va-
por did not increase the concentrations of the interleukins [IL-1 b
median of 64 pg/mL (MMA) vs. 72 pg/mL (air), IL-8 average of
5244 pg/mL (MMA) vs. 5226 pg/mL (air)] in the nasal mucus, or
expression of IL-1 b, IL-6, IL-8, the tumor necrosis factor, monocyte
chemotactic protein, and the cyclooxygenases 1 and 2 (Cox-1 and
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transport time and the odor threshold were also unchanged when
compared with controls. The score in the questionnaire regarding
the provocation of the nasal mucous membrane was discretely in-
creased only at the end of the MMA exposure (median in each case
0 vs. 3 and quartile 1 vs. 0, p < 0.001). The smell of MMA was per-
ceived as unpleasant (median 2 vs. 0, p < 0.001), and the score for
headache was slightly higher during and after the exposure (med-
ian depending upon time, at maximum 0.5 vs. 0, p < 0.001 to
p < 0.05) (Muttray et al., 2007). Although the group size of this
study was small (n = 20), subjects were not routinely exposed to
MMA and therefore would not be susceptible to any inﬂuence of
a ‘‘healthy worker’’ effect. Furthermore, the parameters investi-
gated included sensitive, sub-clinical markers of inﬂammatory irri-
tation that would have been expected to be elevated as early
indications of tissue damage due to MMA.
Twenty-two samples of human nasal respiratory mucosa were
obtained from healthy individuals during surgical intervention.
Primary cell cultures, consisting of respiratory epithelial cells
(80–90%) and ﬁbroblast (10–20%), were prepared and exposed
in vitro to 50 and 200 ppm MMA in vapor phase. Controls were ex-
posed to synthetic air (ﬁltered air supplemented with 5% carbon
dioxide). mRNA expression and cytokine release of inﬂammatory
mediators were quantiﬁed after 4 h and after 24 h. Quantitative
PCR analysis was performed for TNF-a, IL-1b, IL-6, IL-8, MCP-1,
granulocyte–macrophage colony-stimulating factor (GM-CSF),
Cox-1, and Cox-2. Enzyme-linked immunosorbent assays (ELISA)
were performed from culture supernatants for TNF-a, IL-1b, IL-6,
IL-8, MCP-1, and GM-CSF. After 4 h of exposure to 50 ppm MMA,
transient increases in mRNA transcribing for TNF-a, IL-1b, IL-6,
IL-8, and MCP-1 were observed when compared to controls,
although subsequent ELISA analysis did not reveal any signiﬁcant
up-regulation of these cytokines at either concentration and at
any time. There was no increase of inﬂammatory mediators at
200 ppm. The authors claimed that the data suggest that exposure
of human respiratory epithelia in vitro to 50 ppm and to 200 ppm
of MMA does not induce lasting up-regulation of the inﬂammatory
mediators measured in this study, and that consequently, the cur-
rent German workplace exposure limit of 50 ppm appears safe
(Gosepath et al., 2007).
In a crossover design clinical study, 32 healthy test subjects (17
women, 15 men; 15 individuals older than 45 years, 17 of average
age of 24 years) were exposed to MMA, 2-ethyl hexanol (2-EH),
and control (not speciﬁed). The MMA exposures lasted for 4 h and
comprised a variable concentration gradient of 50 ppm average with
4 peaks at 100 ppm. Nasal airway resistance was measured using
rhinomanometry, and samples of the nasal mucus ﬁlm were ob-
tained by nasal lavage ﬂuid before and after exposure. Eye-blink
frequency was measured as an objective quantiﬁcation of eye
irritation during exposure. No dose-dependent changes in any of
the dependent variables were observed with MMA exposure,
whereas exposure to 20 ppm 2-EH signiﬁcantly increased eye-
blink frequency in both age groups and caused a concentration-
independent increase in nasal airway resistance, which was more
pronounced among younger individuals. The biochemical analysis
of the nasal lavage ﬂuid revealed no exposure- or age-related
changes for either chemical (van Thriel et al., 2012).
6. Animal and human dosimetry
There is sufﬁciently strong evidence that the mode of action by
which MMA causes lesions in the olfactory region of the nasal cav-
ity of rats is likely to be the localized metabolism of MMA to the
irritant and corrosive metabolite MAA by non-speciﬁc carboxyles-
terases within the tissue (Andersen and Dennison, 2001). Esterase
activity also occurs in human nasal epithelium. Given that thetypes of nasal epithelial cells found in rats are similar to those of
other mammalian species, including humans – where olfactory
dysfunction is well known in some diseases (Talamo et al., 1994;
Nakashima et al., 1991) and following exposure to certain medica-
tions and environmental agents (Corwin et al., 1995) – it is likely
that the mode of action for MMA toxicity in the nose of rodents will
be relevant to humans. Therefore, workplace exposure to MMA va-
por could result in olfactory tissue damage and resultant dysfunc-
tion (dysosmia), such as that reported in a dental technician by
Braun et al. (2002).
Differences in species sensitivity to MMA-induced olfactory
damage are evident from the available studies in animals using
comparable exposure regimens of 6 h/day, 5 days/week for up to
2 years. No olfactory lesions were observed in golden hamsters ex-
posed up to 400 ppm (1640 mg/m3) MMA for 78 weeks (Lomax
et al., 1997), whereas lesions of mild to moderate severity were ob-
served in F344 rats exposed to 100 and 400 ppm MMA after
2 years, as well as at the interim terminations after 13 and
52 weeks (Lomax, 1992). Lesions were also evident in B6C3F1 mice
at P500 ppm after 102 weeks (NTP, 1986).
This apparent difference in sensitivity between rats/mice and
hamsters invites the question of which species are more compara-
ble to humans. Aside from obvious interspecies differences be-
tween rodents and humans in the nasal anatomy (Harkema,
1991; Harkema and Morgan, 1996) and breathing physiology
(Frederick et al., 1998), there are differences in metabolic activity
that might have a signiﬁcant impact on sensitivity to MMA.
Human nasal tissues are generally accepted to have lower met-
abolic capacity than comparable tissues in rodents (Green and
Mainwaring, 1996; Thornton-Manning and Dahl, 1997; Bogdanffy
et al., 1998; Andersen and Sarangapani, 1999). Comparatively
investigating a speciﬁc biochemical pathway of a toxicant
in vitro is often not possible, owing to the difﬁculty in obtaining
fresh human nasal tissue. Relative carboxylesterase activities of
rat and human epithelial tissues, however, have been developed
for VA and MMA.
Green and Mainwaring (1996), Andersen and Sarangapani
(1999), and Mainwaring et al. (2001) evaluated these biochemical
differences for MMA and reported the distribution of carboxyles-
terases within the nasal cavity of both humans and rats and found
that activity was not evenly distributed throughout the olfactory
epithelium, with regions of higher enzyme activity (MMA-speciﬁc)
in the Bowman’s glands. Andersen and Sarangapani (1999) con-
cluded that total tissue carboxylesterase activity was most impor-
tant in describing the toxicity of MMA, as it is reﬂective of the
widespread tissue damage, including the speciﬁc targeting of the
Bowman’s gland within the submucosa, as observed in the
in vivo studies (Lomax et al., 1997; Mainwaring et al., 2001). There-
fore, species differences in total tissue esterase activity should de-
ﬁne differences in potential toxicity of MMA.
Andersen and Sarangapani (1999) developed a steady-state
PBPK model of inhaled MMA in rodent nasal tissue based upon pul-
monary ventilation rate (taking into consideration the anatomical
speciﬁcities of the rat nose cavity), air-to-liquid phase partition
coefﬁcients, the portion of total cardiac output perfusing the
URT, and the metabolism of MMA in the rat nose. This model incor-
porates the results of computational ﬂuid dynamic modeling of air-
ﬂow to reﬂect the morphology and aerodynamics of the rodent
nasal cavity in vivo and consists of three tissue regions and two
principle ﬂow paths. The dorsal stream ﬂows over a small area of
respiratory epithelium, then over the entire olfactory surface,
while the ventral stream passes over the rest (>80%) of the respira-
tory tissue. Nasal tissue comprises 3 layers: a mucus layer at the
surface, an epithelial tissue compartment, and a blood exchange
region beneath. Metabolism occurs in the epithelial tissue
compartment as well as the blood exchange region. Equations
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the rat nose were based upon those developed by Kimbell et al.
(1993) for formaldehyde. Computations predicted that the tissue
dose for MMA is related to airﬂow, diffusion coefﬁcients, metabolic
parameters, and blood ﬂow (Andersen and Sarangapani, 1999,
2001). Nasal metabolic parameters used substance-speciﬁc data
derived for MMA from in vitro esterase activity in nasal homoge-
nates of both rats and humans, as well as from in vitro esterase
activity in human liver tissue as a surrogate for nasal tissue activity
(Green and Mainwaring, 1996). Human liver tissue was used as a
surrogate for nasal tissue due to the limited supply of fresh human
nasal tissue. It has been shown that for short-chain acrylates and
acetates, including the analogue methyl acrylate, levels of speciﬁc
carboxylesterase activity in the olfactory tissue were comparable
to levels in the liver and greater than those in the kidneys, lung,
or blood (Stott and McKenna, 1985). MMA demonstrates non-
linear extraction in the rat nose, which might be explained by
capacity-limited metabolism. The extraction at low concentrations
(approximately 1 ppm) was about 20%, falling to about 10% at high
concentrations (approximately 600 ppm), consistent with similar
impact of capacity-limited metabolism on uptake, as seen in the
previously discussed in vivo rat data as measured by Morris
(1992) and Morris and Frederick (1995).
The PBPK model was applied to describe human dosimetry by
incorporating information on differences in the nasal tissue metab-
olism of MMA in rats and humans, and taking into consideration
species differences in nasal anatomy, airﬂow patterns through
the nasal cavity, and ventilation rates (for a rat at rest: 197 mL/
min; for a human during light exercise; 13,800 mL/min). Based
on this model of the human nose, it seems that the metabolic clear-
ance is limiting for deposition and that airﬂow has little impact
(Andersen et al., 1999). The rat–human interspecies extrapolation
is based on in vitro data for nasal tissue homogenates as described
above (Green and Mainwaring, 1996).
Model calculations of MMA metabolites in the tissue (tissue
dose) for both species were used to estimate the rat–human dosi-
metric adjustment factor (DAF) for nasal olfactory epithelium. The
estimated DAF was concentration-dependent, varying between 2.4
and 4.76 for a concentration range from 1 to 400 ppm MMA. The
DAF for a ventilation rate equivalent to light exercise was esti-
mated to be 3.02 at 28.4 ppm (benchmark dose for MMA; Andersen
et al., 1999), ranging to 2.98 ppm for heavy exercise (equivalent to
42 L/min). The authors pointed out that the 3.0 estimate for the
DAF is in itself conservative, as it does not take into account that
the breathing pattern in humans is oronasal compared to obliga-
tory nasal in rats, or the fact that by virtue of using esterase levels
in tissue homogenates, the model assumes diffuse enzyme distri-
bution in the submucosal region of the olfactory epithelium in hu-
mans, whereas the available, albeit limited, histochemistry
suggests that it is non-uniform, as it is in the rat. Both of these fac-
tors might increase the DAF signiﬁcantly. For example, if the distri-
bution among tissue layers of esterase activity in humans is
parallel to the distribution observed in rats, with greater esterase
activity in Bowman’s glands (Lomax et al., 1997; Mainwaring
et al., 2001), the DAF is approximately 8.0 (Andersen et al., 1999).
The PBPK model for VA can impart some understanding on the
utility of the model for MMA, although it is important to recognize
that the two PBPK models, while sharing some common features
with respect to known differences between humans and rats
regarding nasal architecture and ﬂow dynamics, etc., do contain
signiﬁcant differences in terms of their inclusion of chemical-spe-
ciﬁc data on deposition, metabolism, and distribution. In their re-
view paper, Andersen et al. (2002) explained that the localization
patterns and degree of uptake of different esters from the nasal
air stream is related to how the degree of extraction interacts with
a number of factors, including airﬂow, tissue diffusion, tissue bloodﬂow, and the capacity and anatomic location of enzymes that
metabolize the esters. VA is a highly extracted (i.e., absorbed well
from vapor phase) ester with almost 100% extraction at exposure
concentrations below 100 ppm. MMA, in contrast, is a poorly ex-
tracted ester with a fractional deposition of between only 10%
and 20% over the concentration range of 25–500 ppm (Morris,
1990; Morris and Frederick, 1995). Since removal of both esters
(MMA and VA) from the airstream is signiﬁcantly dependent upon
metabolism in the nasal tissue, the very different extraction efﬁ-
ciencies reﬂect very different degrees of accessibility of VA and
MMA to esterase-containing tissue compartments throughout the
nasal cavity. The principal conclusion is that there appears to be
esterase activity in the apical regions of nasal epithelia, immedi-
ately adjacent to the mucus layer, that have high afﬁnity for VA
(leading to high extraction by the ﬁrst tissues encountered and les-
ser deposition in tissues encountered subsequently, owing to
depletion of the VA in the airstream), but lesser afﬁnity for MMA
(leading to moderate extraction and much less-pronounced deple-
tion as the airstream passes across nasal tissues). It is metabolism
by the high-afﬁnity surface esterases (discussed by Bogdanffy et al.
(1987)) that leads to high ﬁrst-pass removal of VA from inspired air
and a steep VA concentration gradient from the nasal lumen to the
submucosal tissues and blood exchange regions. It is the steep VA
tissue gradient and strong anterior to posterior gradient in tissue
injury (reﬂecting the high anterior to posterior extraction of VA
through the length of the nasal cavity) that led to the need for
added complexity of the VA PBPK model structure.
The VA PBPK model also has several components accounting for
aldehyde dehydrogenase activity, intracellular buffer capacity, and
proton pump rate and capacity, reﬂecting the multiple mecha-
nisms constituting the overall mode of action (i.e., acetic acid for-
mation and pH changes). In contrast, the MMA model is much
simpler and only requires one component: the rate of metabolism
of MMA to MAA by esterases.7. Weight-of-evidence evaluation
7.1. Animal studies and proposed mode of action
7.1.1. Overall data quality
There are several pre-guideline acute inhalation animal studies,
as well as more recent studies focusing on effects in the nasal cav-
ity. Bearing in mind the objectives of the studies and their concen-
tration selection, they are consistent in identifying local irritant
effects in the nasal cavity of rats as the most sensitive endpoint.
There have been two well-conducted, high-quality carcinogenic-
ity/chronic inhalation studies with MMA in rodents, as well as sev-
eral acute and sub-acute studies speciﬁcally focusing on the effects
of MMA on the URT. These studies are consistent in identifying lo-
cal irritant effects as the most sensitive endpoint following re-
peated exposure to MMA by the inhalation route in rats.
Although Tansy et al. (1980b) observed occasional lung damage
in animals exposed to 116 ppm MMA for 3 or 6 months, these ef-
fects have not been observed at this concentration in any of the
studies reported by other investigators. Tansy et al. (1980b) also
observed comparable effects in the sham-exposed control animals,
albeit to a lesser degree, which is suggestive of a background respi-
ratory infection (Everitt and Richter, 1990), such as that commonly
caused in rats byMycoplasma pulmonis (Cassell, 1982; Cassell et al.,
1985). Thus, it is possible that the occasional lung damage ob-
served by Tansy et al. (1980b) at 116 ppm in rats was due to an
MMA-related exacerbation of a background infection.
Since the study in beagle dogs (Hazelton, 1979a) was limited to
2 animals per group, and because there was no information on the
histopathologic sectioning of the nasal turbinates, this study is
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fects in dogs. As a result, this study is not discussed further.
7.1.2. Relative consistency and speciﬁcity across tissues and species
In all but one of the inhalation studies with MMA in rats, the
standard practice of taking 3–6 cross-sections of the nasal cavity
revealed degenerative lesions of the dorsal olfactory sensory epi-
thelium. Robinson et al. (2003) used a technique that resulted in
taking more sections, and identiﬁed a lesion in the organ of Rodolfo
Masera (also known as the septal organ, or SO). Given the greater
number of sections, it is possible these SO lesions were overlooked
in the other inhalation studies. There are no studies in the litera-
ture, however, addressing the relative sensitivities of the SO and
main olfactory epithelium to chemical insult. Although we can be
relatively certain that the cells of the SO will have carboxylesterases
and the capability of metabolising MMA, it is only possible to
hypothesize that their sensitivity to inhaled MMA might be
broadly comparable to the cells of the main olfactory epithelium.
The SO, however, does not exist in many species, including humans
(Breer and Strotmann, 2005; Harkema et al., 2006; Mast and Sam-
uelsen 2009). Hence, the lesion caused by MMA in the SO in rats is
not relevant to humans and can be discounted as a possible lead
effect.
Since nasal effects were observed at all concentrations tested in
mice (with 500 ppm being the lowest dose tested), the data are
insufﬁcient to conclude that mice are not of similar sensitivity to
the rat with regard to MMA-induced olfactory lesions.
In the 78-week study in golden hamsters, no lesions were ob-
served in the nasal cavities, including the olfactory epithelium, at
6400 ppm, suggesting hamsters are less sensitive than rats and
mice in this regard. Although the morphology (gross anatomy) of
hamsters that could contribute to the difference in sensitivity has
not been characterized to the same extent as in the rat (e.g., air-
ﬂow modeling), the lower sensitivity of hamsters to inhaled
MMA may be due, in part, to physiological differences between
the species. Signiﬁcant differences in certain physiological param-
eters between hamsters and rats have been reported, including in-
spired ﬂow rate (Morris, 1997a), lower ventilation rates and
minute ventilation/lung weight ratio (Yu et al., 1995), alveolar ven-
tilation rate, and cardiac output, as well as other undetermined ba-
sic physiological elements (Thrall et al., 2000). Data on many
compounds point to hamsters being systematically less sensitive
than other rodents to single oral-dose lethality (Rhomberg and
Wolff, 1998).
While there are no data on MMA-speciﬁc esterase activity in
hamsters, comparative carboxylesterase activities in rats and ham-
sters can be estimated from available data on other volatile com-
pounds that are metabolized in the URT. Studies of nasal uptake
and metabolism of acetaldehyde indicate that the inspired ﬂow
rate in the rat is twice that of the hamster (Morris 1997a). It is gen-
erally accepted that tissue/air partition coefﬁcients in hamsters are
comparable to those in rats (Gargas et al., 1986; Evans et al., 1994).
Tissue levels of aldehyde dehydrogenases (enzymes that metabo-
lize acetaldehyde to acetic acid) are higher in the hamster than
in the rat; the rat, however, is more efﬁcient than the hamster at
extracting acetaldehyde, resulting in higher dosage rates being
delivered in the rat compared to those in the hamster at lower con-
centrations (Morris, 1997a).
Studies on ethyl acetate deposition in both hamsters and rats
indicate that similar absorption and metabolism processes occur
in both species. In addition, inhibition of carboxylesterases reduced
ethyl acetate deposition, signifying the importance of localized
metabolism to nasal toxicokinetics. As with acetaldehyde, ethyl
acetate metabolism was shown to be signiﬁcantly higher in the
hamster than in the rat. Deposition of ethyl acetate in the URT
was also higher in the hamster than in the rat, which contraststhe situation observed with acetaldehyde. In the hamster, deposi-
tions averaged between 36% and 72%, of which 63–90% was metab-
olized, while in the rat, deposition averaged between 10% and 35%,
of which 40–65% was metabolized (Morris, 1990). This is inversely
related to observed differences in sensitivity to ethyl acetate, indi-
cating that other factors, such as toxicodynamics, may be impor-
tant. In this regard, it has been reported that the olfactory
mucosa of the rat is particularly sensitive to acids (Morris,
1997b; Stott and McKenna, 1985; Trela and Bogdanffy, 1991).
Based on studies of ethyl acetate and acetaldehyde metabolism,
hamsters do not appear to have a compromised metabolic capacity
in the URT compared to the rat. Although it is not possible to draw
any ﬁrm conclusions, the possibility of relatively higher dosage
rates delivered in the rat compared with the hamster, together
with possible toxicodynamic differences in tissue sensitivity, may
be responsible for the absence of olfactory lesions in hamsters at
400 ppm MMA.
7.2. Human studies
7.2.1. Overall data quality
Since human data reﬂect realistic exposure conditions and do
not require extrapolation of results from animals, they have the
advantage of greater relevance to the immediate question at hand.
On the other hand, because these studies involve people living in
the real world, they are often uncontrolled and observational. Fur-
ther, study subjects often have uncertain exposure estimates or
other exposures or attributes that can make it difﬁcult to deter-
mine whether an association is causal. The studies discussed above
include some of these data quality issues.
For example, the study by Schwartz et al. (1989) involved mixed
exposures (AA, EA, MMA, and MAA), leading to uncertainty as to
the causative agent for observed effects. The study by Gosepath
et al. (2007) is of uncertain relevance because there is no validation
as to the sensitivity of the in vitro technique or concurrent controls
for sensitivity/speciﬁcity. Further, the observation of effects at
50 ppm but not at 200 ppm is indicative of a lack of dose–response,
although the authors suggest this could be due to cytotoxicity at
high in vitro concentrations.
The exposure cohort studied by Muttray et al. (1997) and
Pausch et al. (1994), however, was involved in cast acrylic (poly-
MMA) sheet manufacture, so study participants would have been
predominantly, if not exclusively, exposed to MMA. Furthermore,
these investigators used personal air monitors, which provided
individual exposure information. Muttray et al. (2007) and van
Thriel et al. (2012) used a controlled laboratory exposure setting,
which also provided reliable exposure estimates. There are, how-
ever, some uncertainties regarding exposure measurements within
these studies, including a lack of exposure information for the
Braun et al. (2002) study and omission of an unexposed control
group in several studies (Muttray et al., 2007; Pausch et al.,
1994; Braun et al., 2002).
7.2.2. Relevance of upper respiratory tract effects in humans
There are several studies clearly showing that workers occupa-
tionally exposed to MMA reported experiencing a range of non-
speciﬁed symptoms described as ‘‘irritation’’ of the URT, While this
typically can be interpreted as sensory (trigeminal nerve stimula-
tion) irritation, the speciﬁc reporting of rhinitis, impaired nose
breathing, and dry or bleeding of the nose is suggestive of MMA
causing inﬂammatory irritation and tissue damage in some indi-
viduals. In contrast, there was an absence of any clinical symptoms
of work-related rhinopathy or nasal cavity abnormalities in one
study that included a detailed anamnesis and anterior rhinoscopy
in current MMA-exposed workers, and there was an absence of
changes in a range of sensitive, sub-clinical markers, including
1 Note that, even if one argues that there is more uncertainty for interspecies
variability for the LRT, applying an additional UF of 3 for interspecies variability
would result in a NOAEL of 40 ppm, which is still very close to the human NOAEL of
50 ppm, and consistent with other values derived from rat studies (see Section 8).
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changes in nasal lavage ﬂuids obtained from naïve subjects ex-
posed to 50 ppm MMA.
The absence of work-related rhinopathy in current MMA-ex-
posed workers could be reﬂective of a history of repeated nasal-tis-
sue damage with repair and replacement with less sensitive tissues
types as is observed in rodents. However, if the absence of effects
on sensitive markers of inﬂammation and tissue damage is taken
as being indicative of 50 ppm MMA being well tolerated, then a
more likely explanation is that these historical symptoms were
transient in nature and fully reversible, and the current absence
of clinical symptoms is perhaps reﬂective of the more recent lower
exposure levels in these workplaces.
Regarding the direct effects of MMA on olfactory tissues, there
are understandably no invasive studies in workers since sampling
these tissues is inevitably accompanied by a risk of causing irre-
versible dysfunction. An association between occupational MMA
exposure and dysosmia is suggested by the cross sectional study
of Schwartz et al. (1989) and the case study reported by Braun
et al. (2002). However, neither provides what could be regarded
as compelling evidence. Muttray et al.’s (2007) result that 4 h of
exposure to MMA had no effect on the detection of the odor of
n-butanol in a group of 20 naïve individuals is suggestive of a lack
of effect on olfaction, but is in itself too limited to be conclusive.
This leaves the study of Muttray et al. (1997). In this study, 1 out
of a total of 175 individuals with occupational exposure to MMA
was found to suffer from hyposmia. Considering the duration
(mean: 9.6 ± 7.1 years) and level (650 ppm from 1988 to 1994
and 6100 ppm prior to that time) of exposure, and that that the
Rhino-Test can detect dysfunction in both olfactory and trigemi-
nal nerve stimuli, this study suggests that occupational exposure
to MMA is not associated with signiﬁcant olfactory dysfunction.
7.2.3. Relevance of lower respiratory tract effects in humans
Carboxylesterase activity is found in other parts of the respira-
tory tract in animals and humans, including the trachea and lungs.
Effects on the lower respiratory tract (LRT), including the larynx,
trachea, bronchus, and lungs, have been reported in rats and mice
at P1000 ppm MMA (see Section 3); the NOAEL for these effects
in a 2-year inhalation study in rats is 400 ppm (Hazelton, 1979b).
Therefore, the nasal olfactory and respiratory epithelial effects are
themost sensitive effects in rodents. Since rodents are obligate nose
breathers and humans are nasal and oral breathers, we must con-
sider whether the LRT might be a more sensitive target in humans.
There are several studies clearly showing that workers occupa-
tionally exposed to MMA experienced symptoms indicative of irri-
tation of the LRT. Owing to the retrospective nature of the studies
and the work practices involved, exposure levels have varied con-
siderably, making it impossible to determine a NOAEL. Throat irri-
tation (Lindberg et al., 1991) and throat irritation combined with
frequent cough and sputa (Mizunuma et al., 1993) have been re-
ported in MMA-exposed workers, showing that irritation of the
LRT in humans is possible. In the Lindberg et al. (1991) study, expo-
sures were between 62 and 601 ppm for intervals of approximately
20 min. Although Mizunuma et al. (1993) reported only mean (8-h
TWA) exposure range of between 5 and 112 ppm TWA, there was
no mention of the likelihood of short-term high-exposure levels
beyond 100 ppm, as frequently observed in the other studies of
cast sheet plants (Pickering et al., 1993; Pausch et al., 1994). The
observation of throat irritation, albeit at high MMA concentrations,
is consistent with the presence of non-speciﬁc carboxylesterase
activity throughout the URT and LRT and is the recognized mode
of action for MMA. The data are consistent, with claims by more
than one investigator that irritation is associated with high expo-
sures, potentially in excess of 100 ppm, whether in the form of
short peaks or as a TWA. These clinical and in vitro studies withMMA, albeit limited, are consistent with the ﬁndings of the occu-
pational studies suggesting an absence of not only sensory and
inﬂammatory irritation, but also effects on olfaction at 50 ppm.
Considering that MMA extraction in the URT in rats has been
shown to decrease from 20% to 10% over the range 25–500 ppm
MMA (Morris, 1992), possibly due to saturation of metabolic
capacity or overt tissue damage, the degree of extraction occurring
in the URT, even at higher exposure concentrations, would be ex-
pected to be no greater than 10%. Therefore, even in obligatory na-
sal-breathing rats, at high concentrations, 90% of the MMA gets
past the nose and into the LRT. This translates into an effective
LOAEL/NOAEL of 900 ppm/360 ppm (i.e., 90% of 1000 ppm/90% of
400 ppm) for the LRT in rats based on the chronic studies discussed
in Section 3. When this is compared with the LOAEL/NOAEL of
100 ppm/25 ppm for olfactory effects, it is clear that the LRT is
an order of magnitude less sensitive than the URT in rats.
Since the studies in humans (Section 5) are insufﬁcient to deter-
mine a NOAEL for LRT effects, it is reasonable to extrapolate this
from the rat LOAEL/NOAEL of 900 ppm/360 ppm. Since humans
have an oronasal breathing pattern, there will be very little MMA
extracted from the inhaled air in the URT, so it would be cautious
to assume the LRT is exposed to 100% of the inhaled MMA. Further,
as discussed in Section 8, since the mode of toxicity depends on
quite non-speciﬁc esterase activity in rodents and humans, little
interspecies variability is expected; therefore, an uncertainty factor
(UF) for animals to humans is deemed unnecessary.1 In addition,
there is no reason to expect substantial intra-individual variability
among humans, meaning that a partial intraspecies UF of 3 is
deemed sufﬁciently protective (US EPA, 1998). Therefore, assuming
100% exposure to the rat NOAEL of 360 ppm, and a UF of 3, results
in a NOAEL of 120 ppm for LRT effects in humans. Hence, it is rela-
tively safe to assume that an occupational NOAEL of 50 ppm for
olfactory effects should be protective for effects in the LRT in
humans.
7.2.4. Respiratory allergies and asthma
Clinical reports in the literature suggest that MMA might aug-
ment the development of asthmatic symptoms through an irritant
mechanism, such as that reported for other irritant volatile chem-
icals, cold air, and exercise. Due to the way clinical case studies are
detected, however, they are exclusively retrospective in nature,
and therefore typically not published with reliable personal expo-
sure data. Pickering et al. (1986) is the only publication that con-
tains relevant exposure data (short-term exposures up to
374 ppm) that cited MMA as causing asthma. Therefore, it is not
possible to conclude from the available information that asthmat-
ics are any more sensitive to MMA than normal individuals. The EU
Risk Assessment Report (European Union, 2002) and the review by
Borak et al. (2011) concluded that there is no convincing evidence
that MMA causes asthma.
7.2.5. Conclusion
Overall, there is no convincing evidence that workers exposed
to MMA have experienced signiﬁcant olfactory dysfunction. There
is some indication of an association in the study by Schwartz et al.
(1989), but co-exposure to other volatile toxicants cannot be ex-
cluded. The case report of a dental technician experiencing signif-
icant dysosmia is the strongest evidence of a causal relationship,
but there were no data on the levels of past exposure (Braun
et al., 2002). In addition, the case report appears to describe an iso-
lated individual from an industry that employs many hundreds of
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more, there are two studies in the cast sheet industry (Pausch et al.,
1994; Muttray et al., 1997) that show an absence of olfactory dys-
function among workers exposed to MMA. Although the number of
individuals is arguably limited, the test method used was sufﬁ-
ciently sensitive, the duration of employment sufﬁciently long,
and the level of exposures sufﬁciently high as to expect an effect
on olfaction to be detected. Taken together, they consistently sug-
gest a NOAEL of 50 ppm, since a LOAEL has not been determined in
humans. Further, the observed NOAEL is consistent with studies in
rodents (NOAEL of 25 ppm for olfactory effects), particularly given
the greater sensitivity in rodents compared to humans.
7.3. Toxicokinetic studies
MMA toxicokinetic studies suggest that total tissue esterase
activity deﬁnes differences in MMA toxicity. MMA uptake, distri-
bution, and metabolism parameters in the rat nose were used to
predict nasal tissue dose for MMA. The resulting PBPK model was
further applied to describe human dosimetry by incorporating
information on differences in the nasal tissue metabolism of
MMA in rats and humans and taking into consideration species dif-
ferences in ventilation rates. The model predicts a rat-to-human
DAF of 3.0–8.0, consistent with observed lower sensitivity in the
human occupational studies as compared to rats. Considering the
obvious differences between rodent and human nasal morphology
and breathing pattern, it is therefore not surprising that the PBPK
model predicts signiﬁcant differences between humans and
rodents.
PBPK-predicted differences between rats and humans may be
supported by observations in hamsters, where hamsters have been
found to be less sensitive than rats or mice to MMA-induced nasal
toxicity. The available data suggest that this lower sensitivity is not
due to a reduced metabolic capacity in the nose of hamsters, but
rather to physiological differences that determine local tissue con-
centrations of MMA and its metabolite (MAA) (this has yet to be
tested experimentally).
Further, in consideration of the potential for lower respiratory
effects, rat dosimetry data suggest these effects are not more sen-
sitive than olfactory effects in rats or in humans.
7.4. Weight-of-evidence conclusion
Our WoE evaluation indicates that the various lines of evidence
(human, animal, mode-of-action, and toxicokinetics data), when
considered together, support a common understanding of MMA
toxicity phenomena, and, furthermore, support interpretation of
one another. The WoE suggests olfactory effects are the most
sensitive endpoint in humans resulting from inhalation exposure
to MMA. As discussed herein, local metabolism of MMA to MAA
by carboxylesterases is the likely cause of nasal toxicity (if
sufﬁciently high enough that MAA builds up in the tissue), and
carboxylesterases are found throughout the animal and human
body. The particular sensitivity of nasal olfactory epithelium to
MMA, compared to other tissues, is a function of (1) the direction
of a substantial part of this stream onto particular small regions
of nasal epithelium, and (2) the locally concentrated carboxylester-
ase activity that prompts metabolically enhanced uptake and the
local generation of irritative and corrosive acidic metabolites.
Corrosive acidic metabolites, if produced at rates that exceed the
capacity of defenses, can lead to cytotoxic lesions. On a qualitative
level, these same considerations apply to rodents and humans;
therefore, the MMA mechanism of action is likely the same for
rodents and humans. Owing to differences in rat and human nasal
anatomy and physiology (affecting the airstream patterns vis-à-vis
speciﬁc target tissues and the amount of metabolic activity inthose tissues), MMA dosimetry within the nasal tissue differs be-
tween the two species.
Given that interpretation of the human data are supported by
the other realms of investigation, and that human data are most
relevant to the question at hand, the WoE supports use of human
data for derivation of an OEL for MMA.8. Derivation of an occupational exposure level for MMA
8.1. Derivation from animal data
For derivation of MMA occupational levels from animal data, we
chose 95% Benchmark Concentration Lower Conﬁdence Limits
(BMCLs) from two sources as points-of-departure, all derived from
the rat study by Lomax (1992) and Lomax et al. (1997):
 US EPA (1998) BMCL of 144 mg/m3 for olfactory effects; and
 Dutch Expert Committee on Occupational Safety (DECOS) BMCL
of 482 mg/m3 for nasal respiratory epithelial effects (Health
Council of the Netherlands, 2011).
These values are adjusted based on dosimetry differences be-
tween animals and humans (toxicokinetics differences) through
use of DAFs as described in Andersen et al. (1999). We further ad-
justed the values by applying UFs to account for toxicodynamic dif-
ferences between animals and humans (interspecies UF) and
within the human population (intraspecies UF).
8.1.1. Interspecies extrapolation
8.1.1.1. Based on olfactory effects in rats. The estimated DAF of 3.0
for nasal olfactory epithelium is conservative, as it does not take
into account that the breathing pattern in humans is oronasal com-
pared to obligatory nasal for rats, or that esterase activity in hu-
mans may be greater in the Bowman’s gland (as it is in the rats).
If these factors are taken into consideration, the DAF approximates
to 8.0 (Andersen et al., 1999). We applied a DAF of 3.0 as a conser-
vative adjustment factor to the BMCLs derived from olfactory ef-
fects data (Andersen et al., 1999; US EPA, 1998). To derive an
alternate upper bound exposure level, a DAF of 8.0 was applied
to the BMCLs.
We note that US EPA’s ‘‘Status Report: Advances in Inhalation
Dosimetry of Gases and Vapors with Portal of Entry Effects in the
Upper Respiratory Tract’’ (US EPA, 2009) discusses the application
of PBPK models for derivation of DAFs greater than 1 (e.g., DAF of
1.4 for acrylic acid, and DAF of 3.0 for ethyl acrylate), thus provid-
ing some basis for application of DAFs >1 to derivation of human
toxicity values.
Since we applied a conservative DAF of 3.0 for toxicokinetic dif-
ferences between animals and humans, and since there is no evi-
dent biological basis to expect any substantial species differences
in the toxicological impact of a given target-tissue exposure, any
potential differences in sensitivity between rats and humans be-
yond those that are attributed to dosimetry differences (i.e., toxico-
dynamic differences), are likely covered by use of the more
conservative DAF. Therefore, an additional UF for toxicodynamic
differences between rats and humans is considered unnecessary
when applying a DAF of 3.0. We do, however, apply a UF of 3 for
toxicodynamic differences between rats and humans when apply-
ing a DAF of 8.0 since this is a less conservative DAF.
8.1.1.2. Based on nasal respiratory epithelial effects in rats. The DE-
COS BMCL is based on respiratory epithelial effects; therefore,
the DAF of 3.0 for rat–human differences in delivery to olfactory
tissue does not apply (Health Council of the Netherlands, 2011).
Due to anatomical and MMA-susceptibility differences between
Table 8.1
Derivation of an occupational exposure level for MMA.
Rat studies Human studies (NOAEL)
US EPA BMCL for olfactory
epithelial effects (US EPA, 1998)
DECOS BMCL for nasal respiratory
epithelial effects (Health Council of the Netherlands, 2011)
Point of departure (mg/m3) 144 144 144 482 482 205
Dosimetric adjustment factor (DAF)a,b 3 3 8 None None None
Interspecies uncertainty factor (UF)a,b 1 1 3 1 1 None
Intraspecies uncertainty factor (UF)a,b 3 1 1 3 1 None
Occupational level (mg/m3) 144 432 384 161 482 205
Occupational level (ppm) 35 106 94 39 118 50
Note: 1 ppm = 4.09 mg/m3. BMCL, benchmark concentration lower conﬁdence limit; DECOS, Dutch Expert Committee on Occupational Safety; NOAEL, no observed adverse
effect level.
a The point of departure is multiplied by the DAF (comparable to how US EPA applies the regional gas dose ratio) and divided by the UFs.
b The DAF reﬂects toxicokinetic differences between rats and humans. The UFs represent toxicodynamic differences between rats and humans (interspecies UF) and within
the human population (intraspecies UF).
2 Note that, had we applied a UF of 3 to the values derived from a DAF of 8.0, the
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tory effects to be of ‘‘insufﬁcient relevance to humans,’’ and instead
based their BMCL on respiratory epithelial effects, stating that:
Since no MMA-related susceptibility differences between
rodents and humans have been described for this type of tissue
[respiratory epithelium], the Committee considers these effects
relevant for humans, and based its recommendation on this
effect. (Health Council of the Netherlands, 2011)
DECOS further stated that:
Irritation is a local effect, indicating no necessity to use an addi-
tional uncertainty factor to extrapolate the ﬁndings in animal
studies to the human situation. (Health Council of the Nether-
lands, 2011)
This is generally consistent with UF recommendations for occu-
pational exposure standards discussed by Fairhurst (1995), where
‘‘a small uncertainty factor (perhaps a factor of 1)’’ is recom-
mended when the principal effect from an airborne substance is lo-
cal sensory irritation, with little interspecies variability expected.
Although the observed effects are more than sensory (i.e., inﬂam-
mation and hyperplasia noted in rats), the effects are local, in some
studies shown to be reversible, and, as noted by DECOS (Health
Council of the Netherlands, 2011), little interspecies variability is
expected.
Therefore, a DAF of 1.0 was applied to the DECOS (Health Coun-
cil of the Netherlands, 2011) BMCL, and no UF for interspecies tox-
icodynamic differences was applied.
8.1.2. Intraspecies sensitivity
Overall, there is no evidence that sensitive sub-populations of
adult workers exist. We are not aware of any studies suggesting
non-speciﬁc variability of carboxylesterases in humans. However,
given the non-speciﬁc nature of carboxylesterases and the
straightforward dependence on airﬂow and physicochemical prop-
erties of the agent for delivery of MMA to the target tissues, and lit-
tle intraspecies variance in olfactory degeneration observed in
laboratory animals, little intra-individual variability within a
worker population is expected.
As discussed in the US EPA (1998) MMA reference concentra-
tion (RfC) derivation:
A partial threefold intraspecies uncertainty factor is applied to
the RfC for protection of sensitive subpopulations. This UF is
reduced by extensive human occupational studies and case
reports that consistently identify the irritant properties of
MMA as the principal effect of concern from MMA inhalation
exposures. Little intraspecies variance is observed with respect
to the identiﬁed critical effect, olfactory degeneration in labora-
tory animals (ECETOC, 1995; Lomax et al., 1997), and there is noreason to expect a high degree of intrahuman variability from
this type of effect. Although Pickering et al. (1986) reported
delayed asthmatic response following challenge with MMA,
which would suggest that MMA is a possible respiratory sensi-
tizer, no occupational studies identiﬁed MMA as a respiratory
sensitizer. A partial intraspecies uncertainty factor of 3 is
deemed sufﬁciently protective.
Since the US EPA review in 1998, there has been no additional
evidence that MMA causes asthma (Borak et al., 2011), suggesting
that US EPA’s conclusion that a partial intraspecies UF of 3 is still
sufﬁcient and appropriate for a population of all ages.
Therefore, we include an intraspecies UF range of 1–3 to ac-
count for the possibility of some variability among humans in a
worker population beyond the limited variability within the test
animal population. We applied a UF of 3 to the values derived from
a DAF of 3.0 to present a lower-bound and conservative estimate of
exposure levels from the animal data.2
8.1.3. Calculation of animal-derived values
Below are example calculations of the occupational exposure
levels based on the three animal-derived points-of-departure dis-
cussed above (also shown in Table 8.1). Note that 1 ppm
MMA = 4.09 mg/m3.
From US EPA (1998):
144mg=m3  3ðDAFÞ
3ðintraspecies UFÞ  1ðinterspecies UFÞ ¼ 144 mg=m
3 ¼ 35 ppm
From DECOS (Health Council of the Netherlands, 2011):
482mg=m3  1ðDAFÞ
3ðintraspecies UFÞ  1ðinterspecies UFÞ ¼ 161 mg=m
3 ¼ 39 ppm
The animal-derived values range from 35 to 118 ppm, which is
very close to the human value discussed below. We note that there
is an additional unpublished BMCL for olfactory effects of 116 mg/
m3 cited by Andersen et al. (1999). Application of this BMCL, with
the same UFs used for the US EPA BMCL, results in Occupational
Exposure Levels ranging from 28 to 76 ppm, consistent with the
values shown in Table 8.1.
8.2. Derivation from human data
As discussed in Section 5, the human occupational studies sug-
gest a NOAEL of 50 ppm for MMA, and there is no functional deﬁcit
observed in the human studies. Although toxicity values are often
derived from animal studies because animal studies can beﬁnal values would be similar to the lower range of values presented in the table.
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action can be investigated more thoroughly, the relevance of these
studies is indirect and only useful to the degree that the experi-
mental conditions share underlying causative processes with hu-
mans. In the case of MMA, the causative process
(carboxylesterase mode of action) is very likely the same for ani-
mals and humans, so one could argue that, at least in terms of
mode of action, a human toxicity value derived from animal data
would be appropriate. However, since MMA nasal dosimetry is
quite different for humans and animals, this argument is clearly
indirect and consequently uncertain, requiring the use of a DAF
to estimate human tissue concentrations (via PBPK modeling).
Application of additional UFs is also necessary to ensure protection
of human health (i.e., intraspecies UF to account for variations in
responsiveness between humans over and above the limited vari-
ability within the test animal population).
Therefore, given the necessary adjustments and UFs required to
derive a human value from animal data, it is appropriate, even if
the animal data are strong, to assess whether the human data
are sufﬁciently robust to support derivation of a toxicity value. If
the human data are strong, derivation of a toxicity value from hu-
man data is most appropriate. If the human data are limited, but
nonetheless relatively consistent across studies, and particularly
if the mode of action for humans is known or very likely to be
the same for animals and humans (as is the case for MMA), deriva-
tion of a toxicity value from human data is appropriate. However,
human data should nevertheless be considered in the context of
the animal values to determine relative consistency across values
(i.e., to make sure the animal and human values support each
other). This is, in fact, consistent with our WoE approach to evalu-
ate all realms, or lines, of evidence to be sure the ﬁnal conclusion
reﬂects integration of all relevant data (animal, human, PBPK,
and mode-of-action), and that each line of evidence supports inter-
pretation of another.
Since there is likely to be little intrahuman variability for the
observed olfactory and respiratory epithelial effects (supported
by the fact that US EPA applies a UF of 3 for the entire population,
including children), and it is likely that the intrahuman variability
is captured within the worker population studies, a UF for healthy
working adults is likely less than 3, and quite possibly 1. Therefore,
we do not apply an intraspecies UF to the NOAEL, and recommend
an OEL of 50 ppm for MMA from human data.9. Conclusions
Overall, based on our evaluation of rodent, human, mode-of-
action, and toxicokinetic data, within and across lines of evidence,
the WoE suggests olfactory (and perhaps nasal respiratory epithe-
lial) effects are the most sensitive endpoint in humans resulting
from inhalation exposure to MMA. The apparent lack of concor-
dance between rodents and humans can be explained by differ-
ences in rat and human nasal morphology. Our WoE analysis
indicates that when the available data are integrated (i.e., animal,
human, mode-of-action, and toxicokinetics), the various lines of
evidence inform interpretation of one another and support use of
the human data for derivation of an MMA OEL of 50 ppm. More-
over, when appropriate adjustment factors are applied to the
BMCLs derived from the Lomax (1992) rodent data (i.e., a well-con-
ducted, long-term rodent study, with a large group size, thorough
histopathologic analyses on all relevant tissues, and a clear
dose–response), the resulting exposure levels (35–118 ppm) are
very similar to the human NOAEL and proposed OEL of 50 ppm.
Therefore, the overall conﬁdence in the OEL is medium to high.
Human data are often recommended as the preferred point-
of-departure when setting occupational exposure standards.Certainly, for chemicals that cause only local sensory effects,
human experience can and has been used, so long as the human
effects/exposure data are/were sufﬁciently robust as to enable
the identiﬁcation of a reliable no observable effect concentration
in practice. There is a natural desire, however, to protect workers
prospectively as opposed to studying signiﬁcant toxicity among
those already exposed. Therefore, for chemicals that cause health
effects of greater concern, data generated in standardized animal
tests remain the preferred option because not only can the effects
be reliably reproduced in animal experiments, but use of animal
data also allows for exclusion of confounding factors and examina-
tion of carefully controlled dose–response patterns. The shortcom-
ing of reliance on animal data is the need for animal-to-human
extrapolation, which entails uncertainty about the applicability of
results to humans (interspecies factors) and about the extent to
which other inﬂuential factors absent among the test animals,
but leading to variability between humans (intraspecies factors),
might affect the outcome.
Inhaled MMA causes local effects in the respiratory tract of ro-
dents through metabolism of absorbed gas and generation of MAA.
Since the enzymes responsible are non-speciﬁc carboxylesterases,
this effect can be anticipated to occur ubiquitously in the URT in
mammals, and therefore relevance to humans can be assumed.
Furthermore, since this effect should be relatively straightforward
to detect in humans, worker experience data, if sufﬁciently robust,
should be suitable for use as a point-of-departure when setting a
safe workplace exposure value. The available worker experience
data are consistent with a safe workplace NOAEL of 50 ppm. How-
ever, because effects are observed in rodents at concentrations
lower than the observed human NOAEL, there is a natural bias to-
ward exercising greater precaution. On the other hand, it has been
established that there are pharmacokinetic differences between ro-
dents and humans that indicate that humans are less sensitive than
rodents upon exposure to MMA, so greater precaution may not be
necessary. Supporting this relaxation in precaution is the observa-
tion that although respiratory tract toxicity has been observed in
studies of workers in former occupational settings, these studies
were conducted when air concentrations were considerably higher
than would be experienced by the workforce today and, even then,
these effects were reversible. In the analysis above, we have dem-
onstrated the rationale that for MMA, the best approach for expo-
sure-standard determination is to investigate the commonality and
consistency of animal and human responses to MMA inhalation.
This consistency supports the use of human data for standard
determination, while using the animal data to support the robust-
ness and dependability of the human-based determination.
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